Objective: Detection rate and isolation yield of circulating tumor cell (CTC) are low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches due to limited sample volumes. In this study, we appli...Objective: Detection rate and isolation yield of circulating tumor cell (CTC) are low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches due to limited sample volumes. In this study, we applied the CellCollector to capture CTC in vivo from peripheral blood. Methods: In total, the study included 22 cases with 37 times of detection. All of the patients were newly diagnosed with locally advanced or metastatic SCCHN, including laryngocarcinoma (40.9%, 9/22) and hypopharyngeal carcinoma (59.1%, 13/22). All patients received CTC analysis before treatment. Three patients received induction chemotherapy. Sixteen patients received surgical therapy, of which 13 patients received postoperative detection. Two patients received both induction chemotherapy and surgery treatment. Patients underwent two successive CellCollector applications 24 h before and 7 d after surgical therapy. Nine healthy volunteers were enrolled as the control group. Epidermal growth factor receptor variant type III (EGFRVIII) expression was analyzed with fluorescent dye labeled antibody. Results: With CellCollector isolation, 72.7% (16/22) of the patients were positive for >= 1 CTC (CTC; range, 1-17 cells) before treatments and 46.7% (7/15) of patients were CTC positive for >= 1 CTC (CTC; range, 1-29 cells) after surgical therapy. Moreover, the detection rate of CellCollector (82.4%, 14/17; CTC count range, 0-17) in advanced SCCHN (stage III-IV) was much higher than that in early stages (stage I-II, 40.0%, 2/5; CTC count range, 0-2) (P<0.05). EGFRVIII expression of CTC was also analyzed with fluorescence staining. One CTCEGFRVIII-positive patient was detected from six CTC-positive patients, and the positive expression of EGFRVIII was also found in the tumor tissue of this patient. Conclusions: In vivo detection of CTCs had high sensitivity in SCCHN, which might improve CTC application in clinic.展开更多
颈部鳞癌（squamous cell carcinoma of the head and neck，SCCHN）是较常见的恶性肿瘤，在所有的SCCHN患者中，局部晚期占2／3，其中超过半数的患者会出现局部复发／远处转移。局部晚期SCCHN的疗效及生存问题长期存在若干瓶颈亟待突...颈部鳞癌（squamous cell carcinoma of the head and neck，SCCHN）是较常见的恶性肿瘤，在所有的SCCHN患者中，局部晚期占2／3，其中超过半数的患者会出现局部复发／远处转移。局部晚期SCCHN的疗效及生存问题长期存在若干瓶颈亟待突破，单纯放疗临床预后不理想，同步放化疗提高局部控制率，但带来相关的不良反应降低患者生活质量，展开更多
More than 40% of patients with squamous cell carcinoma of the head and neck (SCCHN) have lymph node metastases (LNM) at the time of diagnosis. Metastasis is one of the main poor prognostic factors of SCCHN.
Background: The prevalence of head and neck cancers in the world is around 57% and predominantly occurs in Asian countries. It accounts for 30% of all cancers in India. The cure rate of locally advanced squamous cell ...Background: The prevalence of head and neck cancers in the world is around 57% and predominantly occurs in Asian countries. It accounts for 30% of all cancers in India. The cure rate of locally advanced squamous cell carcinoma of the head and neck (SCCHN) has only 30% - 60% even after combined therapeutic approaches. Epidermal Growth Factor Receptor (EGFR) antagonists are the most researched targets in the management of head and neck cancers. Claims at superior tumor control and additional survival benefit without any added toxicity make it an attractive option. With this case series we intend to see how nimotuzumab, a humanized monoclonal antibody, fares in difficult cases of head and neck cancers. Case Description: In this case series, total six patients of locally advanced cancer of head and neck region were treated weekly using cisplatin and nimotuzumab concurrently with radiation therapy (RT) for 6 - 7 weeks. Depending upon the disease stage as well as the general condition of the patient, different dose cycles and radiation doses were tailored. Patients were monitored for regular physical examinations and hematological tests followed by pre and post treatment computed tomography (CT) scans, Fludeoxyglucose positive emission tomography (FDG PET-CT) scans, and histopathology. All patients were assessed for toxicities and managed consequently. After completion of radiation and follow-up, 6 weeks later post treatment CT scans were carried out. Conclusion: This case series shows that combination of chemoradiation with nimotuzumab achieved good response rates with no evidence of residual disease/disease progression on follow-up. The patients’ tolerability with combination therapy was good and toxicity was acceptable. Nimotuzumab was found beneficial in combination with chemoradiation for locally advanced head and neck cancers.展开更多
Oral cancer(OC)is one of the most recurrent cancers in the head and neck squamous cancer(SCCHN)category.Recently,the genome-wide association studies(GWAS)have gained growing interest in the scientific community.GWAS h...Oral cancer(OC)is one of the most recurrent cancers in the head and neck squamous cancer(SCCHN)category.Recently,the genome-wide association studies(GWAS)have gained growing interest in the scientific community.GWAS have identified several pathways involved in the interactions among general risk factors and genomic variants affecting SCCHN.This systematic overview aims to critically evaluate the latest data reported within the scientific literature.The aim was to investigate the impact of genetic aspects on SCCHN onset and prognosis,involving other clinical and systemic co-factors.PubMed,Google Scholar,and Cancer Genetics Web databases have been systematically investigated for original articles published in the last two years,reporting studies on the main queries addressed in this work.This review also comparatively describes the impact of environmental and pathological co-factors in different types of cancers,clarifying and updating the role of genetic factors in SCCHN onset and development.The main outcomes reported may be helpful to drive clinicians towards their clinical evaluations for the most appropriate therapeutic approach in SCCHN.展开更多
9术后同期放化疗在高危头颈鳞癌中的应用
Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Tanvetyanon T, Padhya T, McCaffrey J, et al. Head Ne...9术后同期放化疗在高危头颈鳞癌中的应用
Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Tanvetyanon T, Padhya T, McCaffrey J, et al. Head Neck,2014 Mar 12.
尽管头颈鳞癌（SCCHN）术后辅助放疗．但是仍有许多患者出现复发。术后同期放化疗可降低黏膜鳞癌的复发率．该文作者旨在评估术后同期放化疗在皮肤SCCHN的效果。通过对皮肤SCCHN患者术后辅助放疗或同期放化疗的结果进行回顾性队列研究，纳入样本均为临床Ⅲ、Ⅳ期患者，包括转移淋巴结≥2、切缘阳性或包膜外侵犯。展开更多
头颈部鳞癌（squamous cell cancer of the head and neck,SCCHN）每年全球新发生病例约50万，其中2／3为Ⅲ、Ⅳ期。目前国内尚缺少全国范围SCCHN发病率资料，据天津市1981-2002年统计，男、女发病率分别为8．17／10万和4．6／10万，占...头颈部鳞癌（squamous cell cancer of the head and neck,SCCHN）每年全球新发生病例约50万，其中2／3为Ⅲ、Ⅳ期。目前国内尚缺少全国范围SCCHN发病率资料，据天津市1981-2002年统计，男、女发病率分别为8．17／10万和4．6／10万，占所有癌症比例的5．1％和2．7％。展开更多
基金supported by Grants from the National Nature Research Program of China(No.81541057)Science and Technology Department Research Program of Jiangsu Province(No.BK20151080)Science and Technology Department Research Program of Nanjing(No.201402060)
文摘Objective: Detection rate and isolation yield of circulating tumor cell (CTC) are low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches due to limited sample volumes. In this study, we applied the CellCollector to capture CTC in vivo from peripheral blood. Methods: In total, the study included 22 cases with 37 times of detection. All of the patients were newly diagnosed with locally advanced or metastatic SCCHN, including laryngocarcinoma (40.9%, 9/22) and hypopharyngeal carcinoma (59.1%, 13/22). All patients received CTC analysis before treatment. Three patients received induction chemotherapy. Sixteen patients received surgical therapy, of which 13 patients received postoperative detection. Two patients received both induction chemotherapy and surgery treatment. Patients underwent two successive CellCollector applications 24 h before and 7 d after surgical therapy. Nine healthy volunteers were enrolled as the control group. Epidermal growth factor receptor variant type III (EGFRVIII) expression was analyzed with fluorescent dye labeled antibody. Results: With CellCollector isolation, 72.7% (16/22) of the patients were positive for >= 1 CTC (CTC; range, 1-17 cells) before treatments and 46.7% (7/15) of patients were CTC positive for >= 1 CTC (CTC; range, 1-29 cells) after surgical therapy. Moreover, the detection rate of CellCollector (82.4%, 14/17; CTC count range, 0-17) in advanced SCCHN (stage III-IV) was much higher than that in early stages (stage I-II, 40.0%, 2/5; CTC count range, 0-2) (P<0.05). EGFRVIII expression of CTC was also analyzed with fluorescence staining. One CTCEGFRVIII-positive patient was detected from six CTC-positive patients, and the positive expression of EGFRVIII was also found in the tumor tissue of this patient. Conclusions: In vivo detection of CTCs had high sensitivity in SCCHN, which might improve CTC application in clinic.
文摘颈部鳞癌（squamous cell carcinoma of the head and neck，SCCHN）是较常见的恶性肿瘤，在所有的SCCHN患者中，局部晚期占2／3，其中超过半数的患者会出现局部复发／远处转移。局部晚期SCCHN的疗效及生存问题长期存在若干瓶颈亟待突破，单纯放疗临床预后不理想，同步放化疗提高局部控制率，但带来相关的不良反应降低患者生活质量，
文摘More than 40% of patients with squamous cell carcinoma of the head and neck (SCCHN) have lymph node metastases (LNM) at the time of diagnosis. Metastasis is one of the main poor prognostic factors of SCCHN.
文摘Background: The prevalence of head and neck cancers in the world is around 57% and predominantly occurs in Asian countries. It accounts for 30% of all cancers in India. The cure rate of locally advanced squamous cell carcinoma of the head and neck (SCCHN) has only 30% - 60% even after combined therapeutic approaches. Epidermal Growth Factor Receptor (EGFR) antagonists are the most researched targets in the management of head and neck cancers. Claims at superior tumor control and additional survival benefit without any added toxicity make it an attractive option. With this case series we intend to see how nimotuzumab, a humanized monoclonal antibody, fares in difficult cases of head and neck cancers. Case Description: In this case series, total six patients of locally advanced cancer of head and neck region were treated weekly using cisplatin and nimotuzumab concurrently with radiation therapy (RT) for 6 - 7 weeks. Depending upon the disease stage as well as the general condition of the patient, different dose cycles and radiation doses were tailored. Patients were monitored for regular physical examinations and hematological tests followed by pre and post treatment computed tomography (CT) scans, Fludeoxyglucose positive emission tomography (FDG PET-CT) scans, and histopathology. All patients were assessed for toxicities and managed consequently. After completion of radiation and follow-up, 6 weeks later post treatment CT scans were carried out. Conclusion: This case series shows that combination of chemoradiation with nimotuzumab achieved good response rates with no evidence of residual disease/disease progression on follow-up. The patients’ tolerability with combination therapy was good and toxicity was acceptable. Nimotuzumab was found beneficial in combination with chemoradiation for locally advanced head and neck cancers.
文摘Oral cancer(OC)is one of the most recurrent cancers in the head and neck squamous cancer(SCCHN)category.Recently,the genome-wide association studies(GWAS)have gained growing interest in the scientific community.GWAS have identified several pathways involved in the interactions among general risk factors and genomic variants affecting SCCHN.This systematic overview aims to critically evaluate the latest data reported within the scientific literature.The aim was to investigate the impact of genetic aspects on SCCHN onset and prognosis,involving other clinical and systemic co-factors.PubMed,Google Scholar,and Cancer Genetics Web databases have been systematically investigated for original articles published in the last two years,reporting studies on the main queries addressed in this work.This review also comparatively describes the impact of environmental and pathological co-factors in different types of cancers,clarifying and updating the role of genetic factors in SCCHN onset and development.The main outcomes reported may be helpful to drive clinicians towards their clinical evaluations for the most appropriate therapeutic approach in SCCHN.
文摘9术后同期放化疗在高危头颈鳞癌中的应用
Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Tanvetyanon T, Padhya T, McCaffrey J, et al. Head Neck,2014 Mar 12.
尽管头颈鳞癌（SCCHN）术后辅助放疗．但是仍有许多患者出现复发。术后同期放化疗可降低黏膜鳞癌的复发率．该文作者旨在评估术后同期放化疗在皮肤SCCHN的效果。通过对皮肤SCCHN患者术后辅助放疗或同期放化疗的结果进行回顾性队列研究，纳入样本均为临床Ⅲ、Ⅳ期患者，包括转移淋巴结≥2、切缘阳性或包膜外侵犯。
文摘头颈部鳞癌（squamous cell cancer of the head and neck,SCCHN）每年全球新发生病例约50万，其中2／3为Ⅲ、Ⅳ期。目前国内尚缺少全国范围SCCHN发病率资料，据天津市1981-2002年统计，男、女发病率分别为8．17／10万和4．6／10万，占所有癌症比例的5．1％和2．7％。
